Skip to main content

Using Genomic Analysis to Guide Individual Treatment in Glioblastoma

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Using Genomic Analysis to Guide Individual Treatment in Glioblastoma

Safety Study of SEA-CD40 in Cancer Patients

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Safety Study of SEA-CD40 in Cancer Patients

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 177
  • Page 178
  • Page 179
  • Page 180
  • Page 181
  • Page 182
  • Page 183
  • Page 184
  • Page 185
  • …
  • Next page Next
  • Last page Last
Subscribe to